The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical event in patients with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

Please use this link for further information:

clinicaltrials.gov